Ticker: TXMD

TherapeuticsMD, Inc. (NYSE: TXMD) - Quick internal read All amounts below are in thousands of USD and per the company's Form 10-Q for the quarter ended June 30, 2025. What's happening inside: the company has fully transitioned to a royalty model after the Mayne Transaction. Operations are lean (o...

Company Overview TherapeuticsMD, Inc. (NYSE: TXMD) has made significant changes in its operational focus, pivoting from a women’s healthcare company to a pharmaceutical royalty firm as of December 2022. Operating primarily through licensing agreements, the company generates revenue from royalties...